Tolypomycin, a new antibiotic. 3. Isolation and characterization of tolypomycin Y.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000302:isolation & purification / Q000494:pharmacology / Q000633:toxicity; D001412:Bacillus subtilis / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002701:Chloramphenicol / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D007259:Infrared Rays; D051379:Mice; D008826:Microbial Sensitivity Tests; D003904:Mitosporic Fungi / Q000187:drug effects; D009161:Mycobacterium / Q000187:drug effects; D011514:Proteus vulgaris / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012293:Rifampin / Q000302:isolation & purification / Q000494:pharmacology; D012440:Saccharomyces / Q000187:drug effects; D013057:Spectrum Analysis; D013210:Staphylococcus / Q000187:drug effects; D013302:Streptomyces / Q000187:drug effects / Q000378:metabolism; D013752:Tetracycline / Q000494:pharmacology; D014466:Ultraviolet Rays
D000900:Anti-Bacterial Agents; D002701:Chloramphenicol; D013752:Tetracycline; D012293:Rifampin; D003091:Colistin